Galectin Therapeutics Updates Corporate Presentation on Belapectin

An announcement from Galectin Therapeutics ( (GALT) ) is now available.

On May 12, 2025, Galectin Therapeutics announced the availability of its updated corporate presentation on its website, intended for use in investor and analyst meetings. The presentation highlights the company’s focus on advancing Belapectin, a novel galectin-3 inhibitor, which has shown significant efficacy in reducing new varices in patients with MASH cirrhosis and portal hypertension, and potential in cancer treatment. The announcement underscores the company’s strategic positioning in addressing unmet medical needs in these areas, with implications for future clinical trials and potential partnerships.

The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.

Spark’s Take on GALT Stock

According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.

Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.

To see Spark’s full report on GALT stock, click here.

More about Galectin Therapeutics

Galectin Therapeutics Inc. operates in the biopharmaceutical industry, focusing on developing galectin-based therapeutics for chronic liver diseases and cancer. The company’s primary product, Belapectin, is a galectin-3 inhibitor aimed at treating MASH cirrhosis and portal hypertension, with promising results in clinical trials.

Average Trading Volume: 235,759

Technical Sentiment Signal: Sell

Current Market Cap: $87.19M

See more data about GALT stock on TipRanks’ Stock Analysis page.